Palvella Therapeutics Receives FDA Grant for SELVA Trial
Palvella Therapeutics, a clinical-stage biopharmaceutical company focused on novel treatments for rare genetic skin diseases, has achieved a significant milestone with the receipt of initial proceeds from an FDA Orphan Products Grant. This funding will bolster the ongoing Phase 3 SELVA trial investigating QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations (microcystic LMs).
Significance of the FDA Orphan Products Grant
These grants are awarded after thorough scientific assessment by experts in rare diseases and regulatory matters. Palvella’s project was selected from a pool of 51 applicants, marking it as an essential advance in the development of therapies for conditions that currently lack FDA-approved treatments.
The SELVA trial is a 24-week, single-arm, baseline-controlled clinical study, expecting to enroll approximately 40 subjects aged three and above from prominent vascular anomaly centers across the country. Promising results from this trial could potentially lead to the first approved treatment for microcystic lymphatic malformations.
Palvella's Vision and Commitment
Wes Kaupinen, Founder and CEO of Palvella, expressed gratitude for the grant, emphasizing the pressing need for new therapies for this debilitating condition. Currently, there are no FDA-approved options, leaving many patients without effective treatment solutions. QTORIN™ rapamycin aims to fill this critical gap, potentially establishing a new standard of care.
The Nature of Microcystic Lymphatic Malformations
Microcystic LMs represent a severe, progressive genetic disorder influenced by the phosphatidylinositol 3-kinase (PI3K)/mTOR pathway. This condition leads to abnormal lymphatic vessel formation, causing persistent leakage of lymph fluid and frequent infections, which can significantly affect patients' quality of life. To date, over 30,000 individuals in the United States are living with this condition, highlighting the urgency for effective treatments.
About Palvella Therapeutics
Founded by experienced professionals in the rare disease sector, Palvella Therapeutics, Inc. is dedicated to developing innovative therapies for serious genetic skin disorders. Their focus is on a broad pipeline of products derived from the patented QTORIN™ platform, aimed at addressing conditions that lack available treatments.
Currently, their lead candidate, QTORIN™ rapamycin, is under investigation not only in the Phase 3 SELVA trial for microcystic LMs but also in the Phase 2 TOIVA clinical trial aimed at treating cutaneous venous malformations.
Investing in research and development, Palvella is committed to discovering solutions that can enhance outcomes for individuals grappling with these challenging health issues.
Frequently Asked Questions
What is the SELVA trial focusing on?
The SELVA trial is evaluating the effectiveness of QTORIN™ rapamycin in treating microcystic lymphatic malformations, a rare genetic condition.
How much funding did Palvella Therapeutics receive from the FDA?
Palvella Therapeutics was awarded initial proceeds from a grant of up to $2.6 million to support the SELVA trial.
What makes the QTORIN™ rapamycin significant?
QTORIN™ rapamycin targets microcystic lymphatic malformations, where currently no effective treatments exist, representing a potential breakthrough.
Who can participate in the SELVA trial?
The trial is enrolling subjects aged three or older with microcystic lymphatic malformations, primarily at leading vascular anomaly centers.
When is the expected outcome for the SELVA trial results?
Top-line results from the SELVA trial are anticipated in the first quarter of 2026.
